Triple therapy aims to shrink lung cancer before surgery
NCT ID NCT07309952
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This phase II trial tests whether giving radiation, immunotherapy (sintilimab), and chemotherapy before surgery can shrink or eliminate cancer in the lymph nodes of patients with advanced non-small cell lung cancer. The study enrolls 28 adults aged 18-75 with stage IIIB or IIIC cancer that has spread to lymph nodes on the opposite side of the chest. The goal is to make more patients eligible for curative surgery and improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (immunotherapy) plus paclitaxel or pemetrexed (chemotherapy) and stereotactic body radiotherapy (SBRT)
What this could lead to
If this works, it could help shrink advanced lung cancer tumors enough to allow more patients to have surgery, potentially improving survival.
What could go wrong
This is a small early-phase trial with only 28 people, so results may not apply to everyone. The combination of radiation, immunotherapy, and chemotherapy can cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.